A study to investigate longer term dosing of ARB-1467 in combination with tenofovir as well as pegylated interferon
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs ARB 1467 (Primary) ; Interferon; Tenofovir
- Indications Hepatitis B
- Focus Proof of concept; Therapeutic Use
- 02 Nov 2017 According to an Arbutus Biopharma media release, the company expects to initiate this study in the fourth quarter of 2017; also interim results are expected in the second half of 2018, followed by final results in 2019.
- 03 Aug 2017 According to an Arbutus Biopharma media release, this trial is expected to initiate in the fourth quarter of 2017.
- 25 Apr 2017 New trial record